

# Riccardo Nevola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8770120/publications.pdf>

Version: 2024-02-01

46  
papers

1,330  
citations

394421  
19  
h-index

361022  
35  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1840  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bedside ultrasound as a screening test for the diagnosis of catheter-related bloodstream infection (CRBI). Journal of Ultrasound, 2022, 25, 1-7.	1.3	4
2	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. Journal of Viral Hepatitis, 2022, 29, 26-34.	2.0	10
3	Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Reviews in Cardiovascular Medicine, 2022, 23, 0106.	1.4	15
4	Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. Scientific Reports, 2022, 12, 5771.	3.3	7
5	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic? Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 2022, 11, 609.	2.8	7
6	Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	2.4	3
7	Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. Biology, 2022, 11, 805.	2.8	2
8	Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic. Biology, 2022, 11, 800.	2.8	2
9	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. Viruses, 2022, 14, 1096.	3.3	9
10	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. Processes, 2021, 9, 135.	2.8	62
11	Factors Enhancing Treatment of Hepatitis C Virus? Infected Italian People Who Use Drugs: The CLEO-GRECA Experience. American Journal of Gastroenterology, 2021, 116, 1248-1255.	0.4	5
12	Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Review of Gastroenterology and Hepatology, 2021, 15, 643-656.	3.0	8
13	Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Medica, 2021, 112, 188-200.	0.9	13
14	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovascular Diabetology, 2021, 20, 145.	6.8	91
15	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2345-2353.	2.6	40
16	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. PLoS ONE, 2021, 16, e0256903.	2.5	8
17	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. Life, 2021, 11, 17.	2.4	6
18	A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses, 2021, 13, 2249.	3.3	42

#	ARTICLE	IF	CITATIONS
19	Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development. Journal of Hepatology, 2020, 73, S623-S624.	3.7	0
20	Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open, 2020, 4, 713-721.	1.6	18
21	Unusual liver-related heart injury. JGH Open, 2020, 4, 1240-1241.	1.6	0
22	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. Diabetes, Obesity and Metabolism, 2020, 22, 2408-2416.	4.4	58
23	Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1806-1812.	2.6	2
24	The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. Journal of Diabetes Research, 2020, 2020, 1-8.	2.3	106
25	Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience. Journal of Hepatology, 2020, 73, S366.	3.7	0
26	Metformin: An old drug against old age and associated morbidities. Diabetes Research and Clinical Practice, 2020, 160, 108025.	2.8	64
27	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis, 2020, 296, 40-47.	0.8	78
28	Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. PLoS ONE, 2020, 15, e0243700.	2.5	36
29	Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine, 2020, 1, .	1.5	37
30	Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. Nutrients, 2019, 11, 1878.	4.1	14
31	Metformin lactic acidosis: Should we still be afraid?. Diabetes Research and Clinical Practice, 2019, 157, 107879.	2.8	30
32	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. Journal of Translational Medicine, 2019, 17, 292.	4.4	49
33	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Digestive Diseases and Sciences, 2019, 64, 3013-3019.	2.3	33
34	Validation of the BAP-65 score for prediction of in-hospital death or use of mechanical ventilation in patients presenting to the emergency department with an acute exacerbation of COPD: a retrospective multi-center study from the Italian Society of Emergency Medicine (SIMEU). European Journal of Internal Medicine, 2019, 61, 62-68.	2.2	5
35	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Journal of Hepatology, 2018, 69, 18-24.	3.7	98
36	Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. Digestive and Liver Disease, 2018, 50, 31.	0.9	0

#	ARTICLE	IF	CITATIONS
37	COPD exacerbations in the emergency department: Epidemiology and related costs. A retrospective cohort multicentre study from the Italian Society of Emergency Medicine (SIMEU). <i>European Journal of Internal Medicine</i> , 2018, 51, 74-79.	2.2	13
38	Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1379-1382.	2.8	64
39	Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?. <i>World Journal of Gastroenterology</i> , 2018, 24, 4617-4621.	3.3	31
40	Endotoxemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. <i>Infection</i> , 2018, 46, 793-799.	4.7	15
41	How does antiviral therapy for hepatitis B influence liver stiffness?. <i>Future Virology</i> , 2018, 13, 521-523.	1.8	0
42	Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease. <i>Hepatoma Research</i> , 2018, 4, 55.	1.5	13
43	Chronic Hepatitis C Virus Infection and Depression. <i>Clinics in Liver Disease</i> , 2017, 21, 517-534.	2.1	46
44	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1458.	3.3	38
45	Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. <i>World Journal of Gastroenterology</i> , 2015, 21, 2269.	3.3	134
46	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. <i>World Journal of Hepatology</i> , 2014, 6, 677.	2.0	14